Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Q2 2022 Earnings Conference Call August 2, 2022 8:30 AM ET

Company Participants

Sujal Patel - Founder and Chief Executive Officer

Anna Mowry - Chief Financial Officer

Parag Mallick - Founder and Chief Scientist

Conference Call Participants

Stephanie Yan - Cowen and Company, LLC

Tejas Savant - Morgan Stanley

David Delahunt - Goldman Sachs

Operator

Thank you for standing by, and welcome to the Nautilus Biotechnology Second Quarter 2022 Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speakers' presentation, there will be a question-and-answer session. [Operator Instructions] As a reminder, today's program is being recorded.

And now I would like to introduce your host for today's program, [Alex Carr], Investor Relations. Please go ahead.

Unidentified Company Representative

Thank you. Earlier today, Nautilus released financial results for the quarter ended June 30, 2022. If you haven't received this news release, or if you'd like to be added to the Company's distribution list, please send an email to investorrelations@nautilus.bio. Joining me today from Nautilus are Sujal Patel, Co-Founder and CEO and Anna Mowry, Chief Financial Officer; Co-Founder and Chief Scientist, Parag Mallick will be available during Q&A.

Before we begin, I'd like to remind you that management will make statements during this call that are forward-looking within the meaning of the federal securities laws. These statements involve material risks and uncertainties that could cause actual results or events to materially differ from those anticipated. Additional information regarding these risks and uncertainties appears in the section entitled Forward-Looking Statements in the press release Nautilus issued today. Except as required by law, Nautilus disclaims any intention or obligation to update or revise any financial or product pipeline projections or other forward-looking statements, whether because of new information, future events, or otherwise. This conference call contains time-sensitive information and is accurate only as of the live broadcast, August 2, 2022.

With that, I'll turn the call over to Sujal.

Sujal Patel

Thanks, Alex. Good morning, and thank you to everyone for joining us today. On this call, we will share our results for the second quarter of 2022, provide some insight as to how we are tightly managing the business in response to macroeconomic challenges and update you on the revised timing of our commercial launch and revenue expectations. But first, I want to thank our teams in the Bay Area and Seattle for their continued solid progress against our key scientific and business objectives. I look forward to the day where their work is in the hands of researchers who will leverage our platform to explore important biological questions, once thought unanswerable and to reveal insights, once thought unknowable.